In vivo efficacy of a chitosan/IL-12 adjuvant system for protein-based vaccines

Biomaterials

Volumn 32, Issue 3, 2011, Pages 926-932

  Heffernan, Michael J ^a   Zaharoff, David A ^a   Fallon, Jonathan K ^a   Schlom, Jeffrey ^a   Greiner, John W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chitosan; Drug delivery; Immunostimulation; Interleukin 12; Polysaccharide; Vaccine

Indexed keywords

ANTIBODY RESPONSE; CHITOSAN SOLUTION; CLASS I; CYTOKINES; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN-VIVO; INTERLEUKIN-12; MODEL PROTEINS; OVALBUMINS; PENTAMERS; RECOMBINANT PROTEIN; SPLENOCYTE PROLIFERATION; T-CELL RESPONSE;

ANTIGENS; CHITIN; CHITOSAN; DRUG DELIVERY; IMMUNOLOGY; PROTEINS;

VACCINES;

CHITOSAN; GAMMA INTERFERON; GLUTAMIC ACID; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHITOSAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; PROTEINS; VACCINES;

MURINAE;

EID: 78549270045     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.09.058     Document Type: Article

References (25)

1. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(1):23-32.
2. O'Hagan D.T., De Gregorio E. The path to a successful vaccine adjuvant - 'the long and winding road'. Drug Discov Today 2009, 14(11-12):541-551.
3. Lore K., Karlsson Hedestam G.B. Novel adjuvants for B cell immune responses. Curr Opin HIV AIDS 2009, 4(5):441-446.
4. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11(4 Suppl.):S63-S68.
5. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3(2):133-146.
6. Scott P., Trinchieri G. IL-12 as an adjuvant for cell-mediated immunity. Semin Immunol 1997, 9(5):285-291.
7. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994, 263(5144):235-237.
8. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.E., et al. Expression cloning of a protective Leishmania antigen. Science 1995, 268(5210):563-566.
9. Mountford A.P., Anderson S., Wilson R.A. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J Immunol 1996, 156(12):4739-4745.
10. Mahon B.P., Ryan M.S., Griffin F., Mills K.H. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells. Infect Immun 1996, 64(12):5295-5301.
11. Schijns V.E., Haagmans B.L., Horzinek M.C. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice. J Immunol 1995, 155(5):2525-2532.
12. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173.
13. Jankovic D., Caspar P., Zweig M., Garcia-Moll M., Showalter S.D., Vogel F.R., et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol 1997, 159(5):2409-2417.
14. Gurunathan S., Prussin C., Sacks D.L., Seder R.A. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998, 4(12):1409-1415.
15. Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol 2010, 56(3):290-299.
16. Azab A.K., Doviner V., Orkin B., Kleinstern J., Srebnik M., Nissan A., et al. Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. J Biomed Mater Res A 2007, 83(2):414-422.
17. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25(11):2085-2094.
18. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine 2007, 25(52):8673-8686.
19. Zaharoff D.A., Hoffman B.S., Hooper H.B., Benjamin C.J., Khurana K.K., Hance K.W., et al. Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12. Cancer Res 2009, 69(15):6192-6199.
20. Zaharoff D., Hance K., Rogers C., Schlom J., Greiner J. Intratumoral immunotherapy of established solid tumors with chitosan/IL-12. J Immunother 2010, 33(7):697-705.
21. Klinman D.M., Klaschik S., Sato T., Tross D. CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases. Adv Drug Deliv Rev 2009, 61(3):248-255.
22. Mocikat R., Braumuller H., Gumy A., Egeter O., Ziegler H., Reusch U., et al. Natural killer cells activated by MHC class I(low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003, 19(4):561-569.
23. Phase I. Norwalk vaccine study Available from:, [accessed 03.08.10]. http://www.clinicaltrials.gov/ct2/show/NCT00806962%3fterm%3DNCT00806962%26rank%3D1.
24. McNeela E.A., Jabbal-Gill I., Illum L., Pizza M., Rappuoli R., Podda A., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 2004, 22(8):909-914.
25. Read R.C., Naylor S.C., Potter C.W., Bond J., Jabbal-Gill I., Fisher A., et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine 2005, 23(35):4367-4374.